Literature DB >> 18615144

Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

J Manzanares1, Md Julian, A Carrascosa.   

Abstract

Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. Preclinical and clinical studies have suggested that they may result useful to treat diverse diseases, including those related with acute or chronic pain. The discovery of cannabinoid receptors, their endogenous ligands, and the machinery for the synthesis, transport, and degradation of these retrograde messengers, has equipped us with neurochemical tools for novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects with other systems that influence analgesia, especially the endogenous opioid system. Cannabinoid receptor agonists have shown therapeutic value against inflammatory and neuropathic pains, conditions that are often refractory to therapy. Although the psychoactive effects of these substances have limited clinical progress to study cannabinoid actions in pain mechanisms, preclinical research is progressing rapidly. For example, CB(1)mediated suppression of mast cell activation responses, CB(2)-mediated indirect stimulation of opioid receptors located in primary afferent pathways, and the discovery of inhibitors for either the transporters or the enzymes degrading endocannabinoids, are recent findings that suggest new therapeutic approaches to avoid central nervous system side effects. In this review, we will examine promising indications of cannabinoid receptor agonists to alleviate acute and chronic pain episodes. Recently, Cannabis sativa extracts, containing known doses of tetrahydrocannabinol and cannabidiol, have granted approval in Canada for the relief of neuropathic pain in multiple sclerosis. Further double-blind placebo-controlled clinical trials are needed to evaluate the potential therapeutic effectiveness of various cannabinoid agonists-based medications for controlling different types of pain.

Entities:  

Keywords:  Analgesia; cannabidiol; cannabinoid receptor; cannabis; endocannabinoid; inflammatory pain; neuropathic pain; tetrahydrocannabinol

Year:  2006        PMID: 18615144      PMCID: PMC2430692          DOI: 10.2174/157015906778019527

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


  173 in total

1.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.

Authors:  B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

2.  Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice.

Authors:  R B Raffa; D J Stone; S J Hipp
Journal:  Neurosci Lett       Date:  1999-03-19       Impact factor: 3.046

3.  Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study.

Authors:  A G Hohmann; M Herkenham
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

4.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

5.  Antinociceptive, subjective and behavioral effects of smoked marijuana in humans.

Authors:  M K Greenwald; M L Stitzer
Journal:  Drug Alcohol Depend       Date:  2000-06-01       Impact factor: 4.492

6.  Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.

Authors:  D G Deutsch; S Lin; W A Hill; K L Morse; D Salehani; G Arreaza; R L Omeir; A Makriyannis
Journal:  Biochem Biophys Res Commun       Date:  1997-02-03       Impact factor: 3.575

7.  Effect of benzopyranoperidine, a delta-9-THC congener, on pain.

Authors:  P R Jochimsen; R L Lawton; K VerSteeg; R Noyes
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

8.  mu-Opioid agonists inhibit spinal trigeminal substantia gelatinosa neurons in guinea pig and rat.

Authors:  T J Grudt; J T Williams
Journal:  J Neurosci       Date:  1994-03       Impact factor: 6.167

9.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

Authors:  A Zimmer; A M Zimmer; A G Hohmann; M Herkenham; T I Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Structural determinants for recognition and translocation by the anandamide transporter.

Authors:  D Piomelli; M Beltramo; S Glasnapp; S Y Lin; A Goutopoulos; X Q Xie; A Makriyannis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

View more
  57 in total

1.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

2.  Cannabichromene is a cannabinoid CB2 receptor agonist.

Authors:  Michael Udoh; Marina Santiago; Steven Devenish; Iain S McGregor; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-11-21       Impact factor: 8.739

3.  An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain.

Authors:  Yong Fang Zhu; Katja Linher-Melville; Mohammad Javad Niazmand; Manu Sharma; Ayesha Shahid; Kan Lun Zhu; Natalka Parzei; Jesse Sidhu; Christeene Haj; Raphael Mechoulam; Gurmit Singh
Journal:  Br J Pharmacol       Date:  2020-03-08       Impact factor: 8.739

Review 4.  Pharmacological options for the management of refractory cancer pain-what is the evidence?

Authors:  B Afsharimani; K Kindl; P Good; J Hardy
Journal:  Support Care Cancer       Date:  2015-03-07       Impact factor: 3.603

Review 5.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

6.  Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Christian A Kell; Ulrike Nöth; Johannes Vermehren; Jochen Kaiser; Ralf Deichmann; Jörn Lötsch
Journal:  Neuropsychopharmacology       Date:  2015-10-30       Impact factor: 7.853

Review 7.  Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.

Authors:  Gernot F Grabner; Robert Zimmermann; Rudolf Schicho; Ulrike Taschler
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

8.  Association between cannabis laws and opioid prescriptions among privately insured adults in the US.

Authors:  Mukaila A Raji; N Ogechi Abara; Habeeb Salameh; Jordan R Westra; Yong-Fang Kuo
Journal:  Prev Med       Date:  2019-05-21       Impact factor: 4.018

9.  A novel near-infrared fluorescence imaging probe that preferentially binds to cannabinoid receptors CB2R over CB1R.

Authors:  Xiaoxi Ling; Shaojuan Zhang; Pin Shao; Weixia Li; Ling Yang; Ying Ding; Cong Xu; Nephi Stella; Mingfeng Bai
Journal:  Biomaterials       Date:  2015-04-28       Impact factor: 12.479

10.  Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey.

Authors:  Janet Weber; Marcus Schley; Matthias Casutt; Helmut Gerber; Guido Schuepfer; Roman Rukwied; Wolfgang Schleinzer; Michael Ueberall; Christoph Konrad
Journal:  Anesthesiol Res Pract       Date:  2009-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.